MAPT and Alzheimer disease: Another study found that SLAB51 inhibits cholesterol biosynthesis, lowers the ω-6/ ω-3 fatty acid ratio, improves neuroinflammation and oxidative stress, ultimately reducing Aβ and tau aggregation, and slowing down AD progression [46].